SI2847190T1 - Biciklično substituirani uracili in njihova uporaba - Google Patents

Biciklično substituirani uracili in njihova uporaba

Info

Publication number: SI2847190T1
Authority: SI; Slovenia
Prior art keywords: substituted uracils; bicyclically substituted; bicyclically; uracils; substituted
Prior art date: 2012-05-09

Application number

SI201330233A

Other languages

English (en)

Inventor

Chantal Furstner

Jens Ackerstaff

Alexander Straub

Heinrich Meier

Hanna Tinel

Katja Zimmermann

Adrian Tersteegen

Dmitry Zubov

Raimund Kast

Jens Schamberger

Martina Schafer

Kirsten Borngen

Original Assignee

Bayer Pharma Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-09

Filing date

2013-05-03

Publication date

2016-08-31

2013-05-03 Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft

2016-08-31 Publication of SI2847190T1 publication Critical patent/SI2847190T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SI201330233A 2012-05-09 2013-05-03 Biciklično substituirani uracili in njihova uporaba SI2847190T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP12167231		2012-05-09
PCT/EP2013/059286 WO2013167495A1 (de)	2012-05-09	2013-05-03	Bicyclisch-substituierte uracile und ihre verwendung
EP13720407.9A EP2847190B1 (de)	2012-05-09	2013-05-03	Bicyclisch-substituierte uracile und ihre verwendung

Publications (1)

Publication Number	Publication Date
SI2847190T1 true SI2847190T1 (sl)	2016-08-31

Family

ID=48289199

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201330934T SI3045456T1 (sl)	2012-05-09	2013-05-03	Biciklično substituirani uracili in njihova uporaba
SI201330233A SI2847190T1 (sl)	2012-05-09	2013-05-03	Biciklično substituirani uracili in njihova uporaba

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI201330934T SI3045456T1 (sl)	2012-05-09	2013-05-03	Biciklično substituirani uracili in njihova uporaba

Country Status (43)

Country	Link
US (5)	US9481672B2 (sl)
EP (2)	EP3045456B1 (sl)
JP (2)	JP6141414B2 (sl)
KR (1)	KR102083281B1 (sl)
CN (2)	CN104395310B (sl)
AP (1)	AP2014008096A0 (sl)
AR (1)	AR090994A1 (sl)
AU (2)	AU2013258223B2 (sl)
BR (1)	BR112014028086B1 (sl)
CA (1)	CA2872906C (sl)
CL (1)	CL2014003031A1 (sl)
CO (1)	CO7131375A2 (sl)
CR (1)	CR20140513A (sl)
CU (1)	CU20140129A7 (sl)
CY (2)	CY1118900T1 (sl)
DK (2)	DK3045456T3 (sl)
DO (1)	DOP2014000255A (sl)
EA (2)	EA031222B1 (sl)
EC (1)	ECSP14026138A (sl)
ES (2)	ES2657315T3 (sl)
HR (2)	HRP20160796T1 (sl)
HU (2)	HUE035462T2 (sl)
IL (2)	IL235438A (sl)
JO (1)	JO3290B1 (sl)
LT (1)	LT3045456T (sl)
MX (2)	MX357712B (sl)
MY (1)	MY181828A (sl)
NO (1)	NO3045456T3 (sl)
NZ (1)	NZ701700A (sl)
PE (1)	PE20142301A1 (sl)
PH (1)	PH12014502496B1 (sl)
PL (2)	PL2847190T3 (sl)
PT (2)	PT3045456T (sl)
RS (2)	RS54901B1 (sl)
SA (1)	SA113340533B1 (sl)
SG (1)	SG10202003175QA (sl)
SI (2)	SI3045456T1 (sl)
TN (1)	TN2014000470A1 (sl)
TW (2)	TWI635085B (sl)
UA (1)	UA112897C2 (sl)
UY (1)	UY34797A (sl)
WO (1)	WO2013167495A1 (sl)
ZA (1)	ZA201408146B (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA112897C2 (uk) *	2012-05-09	2016-11-10	Байєр Фарма Акцієнгезелльшафт	Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
CA2929753A1 (en) *	2013-11-08	2015-05-14	Bayer Pharma Aktiengesellschaft	Substituted uracils and use thereof
HK1224288A1 (zh) *	2013-11-08	2017-08-18	Bayer Pharma Aktiengesellschaft	作为类糜蛋白酶抑制剂的取代的尿嘧啶
SI3066097T1 (sl) *	2013-11-08	2017-12-29	Bayer Pharma Aktiengeselschaft	Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-((1r)-4 -(trifluormetil)-2,3-dihidro-1H-inden-1-il)-1,2,3,4-tetrahidropirimidin- 5-ogljikove kisline
HK1223610A1 (zh) *	2013-11-08	2017-08-04	Bayer Pharma Aktiengesellschaft	取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途
WO2017162661A1 (en)	2016-03-22	2017-09-28	Bayer Pharma Aktiengesellschaft	1h-benzo[de]isoquinoline-1,3(2h)-diones
EP3338780A1 (de) *	2016-12-20	2018-06-27	Bayer Pharma Aktiengesellschaft	Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en)	2017-04-27	2018-11-01	Bayer Aktiengesellschaft	Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
BR112020022340A2 (pt)	2018-05-15	2021-02-02	Bayer Aktiengesellschaft	benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
CN110229067A (zh) *	2019-06-05	2019-09-13	南京焕然生物科技有限公司	一种2-氨基茚制备方法
CN113811530B (zh) *	2019-07-03	2022-07-19	南京明德新药研发有限公司	作为糜酶抑制剂的嘧啶酮类化合物及其应用
US11618751B1 (en)	2022-03-25	2023-04-04	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111440141A (zh) *	2020-05-20	2020-07-24	安徽泽升科技有限公司	一种羟甲基取代芳杂环类化合物的制备方法
WO2022135502A1 (zh) *	2020-12-25	2022-06-30	广东东阳光药业有限公司	多取代的尿嘧啶衍生物及其用途
WO2022135514A1 (zh) *	2020-12-25	2022-06-30	广东东阳光药业有限公司	多取代的尿嘧啶衍生物及其用途
WO2022135534A1 (zh) *	2020-12-25	2022-06-30	广东东阳光药业有限公司	取代的含氮双环化合物及其用途
US11319319B1 (en)	2021-04-07	2022-05-03	Ventus Therapeutics U.S., Inc.	Compounds for inhibiting NLRP3 and uses thereof
US20250051367A1 (en) *	2021-12-06	2025-02-13	Pretzel Therapeutics, Inc.	Heterocycle-containing lonp1 inhibitor compounds, uses and methods
CN119278042A (zh) *	2022-04-05	2025-01-07	索克普拉健康与人文科学公司	用于血栓性或血栓栓塞性病症中血栓的选择性溶解的糜蛋白酶抑制剂
US12331048B2 (en)	2022-10-31	2025-06-17	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
US6114532A (en)	1998-02-03	2000-09-05	Boehringer Ingelheim Pharma Kg	Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
US6458952B1 (en)	1999-05-19	2002-10-01	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
EP1219611A4 (en)	1999-09-03	2003-03-19	Ajinomoto Kk	NEW PROCESSES FOR THE PRODUCTION OF OXAZEPINE DERIVATIVES
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0021315D0 (en)	2000-08-30	2000-10-18	Dainippon Pharmaceutical Co	Heterocyclic compounds and intermediates thereof
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2003017508A (ja)	2001-07-05	2003-01-17	Nec Corp	電界効果トランジスタ
AR038536A1 (es)	2002-02-25	2005-01-19	Upjohn Co	N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
JP2003342265A (ja) *	2002-05-22	2003-12-03	Senju Pharmaceut Co Ltd	トリアゾリジン誘導体およびその医薬用途
AU2003290735A1 (en)	2002-12-06	2004-06-30	Eli Lilly And Company	Inhibitors of monoamine uptake
EP1666067A4 (en) *	2003-08-22	2009-07-22	Teijin Pharma Ltd	MEDICAMENT WITH CHYMASE INHIBITOR AS AN ACTIVE SUBSTANCE
DE102004004928A1 (de)	2004-01-31	2005-08-18	Bayer Healthcare Ag	Dibenzoxazepine II
WO2005092899A1 (en)	2004-03-26	2005-10-06	Methylgene Inc.	Inhibitors of histone deacetylase
US7507748B2 (en)	2004-07-22	2009-03-24	Amgen Inc.	Substituted aryl-amine derivatives and methods of use
US20070078121A1 (en)	2004-12-23	2007-04-05	Flynn Daniel L	Enzyme modulators and treatments
WO2006119504A2 (en)	2005-05-04	2006-11-09	Renovis, Inc.	Fused heterocyclic compounds, and compositions and uses thereof
WO2007007161A2 (en) *	2005-07-08	2007-01-18	Orchid Research Laboratories Limited	Novel bio-active derivatives
WO2007120339A1 (en)	2005-12-19	2007-10-25	Genentech, Inc.	Pyrimidine kinase inhibitors
ES2331930T3 (es)	2006-02-14	2010-01-20	Pfizer Products Inc.	Oxazolidinonas con benzoxazinonas y benzoxazepinonas como agentes antibacterianos.
AR061570A1 (es) *	2006-06-23	2008-09-03	Smithkline Beecham Corp	Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
US7790756B2 (en)	2006-10-11	2010-09-07	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en)	2006-11-10	2006-12-20	Addex Pharmaceuticals Sa	Novel heterocyclic derivatives
AU2008219166B2 (en)	2007-02-16	2013-05-16	Amgen Inc.	Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
CA2683785A1 (en)	2007-04-13	2008-10-23	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
WO2009049112A1 (en)	2007-10-10	2009-04-16	Smithkline Beecham Corporation	Prolyl hydroxylase inhibitors
MX2010003346A (es)	2007-10-19	2010-04-09	Boehringer Ingelheim Int	Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
CN102015682B (zh) *	2008-05-05	2014-07-16	埃科特莱茵药品有限公司	作为肾素抑制剂的3,4-取代的哌啶衍生物
CA2727340A1 (en)	2008-06-25	2009-12-30	Daiichi Sankyo Company, Limited	Carboxylic acid compound
DE102008030091B4 (de) *	2008-06-25	2011-03-03	Resprotect Gmbh	Uracilderivate und deren Verwendung
UA112897C2 (uk) *	2012-05-09	2016-11-10	Байєр Фарма Акцієнгезелльшафт	Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

2013
- 2013-03-05 UA UAA201413167A patent/UA112897C2/uk unknown
- 2013-05-03 MX MX2014013571A patent/MX357712B/es active IP Right Grant
- 2013-05-03 MY MYPI2014703273A patent/MY181828A/en unknown
- 2013-05-03 HU HUE16154186A patent/HUE035462T2/en unknown
- 2013-05-03 EA EA201790032A patent/EA031222B1/ru not_active IP Right Cessation
- 2013-05-03 US US14/399,945 patent/US9481672B2/en active Active
- 2013-05-03 MX MX2018008811A patent/MX367599B/es unknown
- 2013-05-03 JP JP2015510754A patent/JP6141414B2/ja active Active
- 2013-05-03 ES ES16154186.7T patent/ES2657315T3/es active Active
- 2013-05-03 PL PL13720407.9T patent/PL2847190T3/pl unknown
- 2013-05-03 EP EP16154186.7A patent/EP3045456B1/de active Active
- 2013-05-03 RS RS20160510A patent/RS54901B1/sr unknown
- 2013-05-03 PE PE2014001986A patent/PE20142301A1/es active IP Right Grant
- 2013-05-03 SG SG10202003175QA patent/SG10202003175QA/en unknown
- 2013-05-03 BR BR112014028086-0A patent/BR112014028086B1/pt active IP Right Grant
- 2013-05-03 KR KR1020147034155A patent/KR102083281B1/ko active Active
- 2013-05-03 AP AP2014008096A patent/AP2014008096A0/xx unknown
- 2013-05-03 SI SI201330934T patent/SI3045456T1/sl unknown
- 2013-05-03 DK DK16154186.7T patent/DK3045456T3/da active
- 2013-05-03 HR HRP20160796TT patent/HRP20160796T1/hr unknown
- 2013-05-03 CN CN201380034776.9A patent/CN104395310B/zh active Active
- 2013-05-03 EA EA201492040A patent/EA030383B9/ru not_active IP Right Cessation
- 2013-05-03 SI SI201330233A patent/SI2847190T1/sl unknown
- 2013-05-03 LT LTEP16154186.7T patent/LT3045456T/lt unknown
- 2013-05-03 PT PT161541867T patent/PT3045456T/pt unknown
- 2013-05-03 DK DK13720407.9T patent/DK2847190T3/en active
- 2013-05-03 PT PT137204079T patent/PT2847190T/pt unknown
- 2013-05-03 NZ NZ701700A patent/NZ701700A/en unknown
- 2013-05-03 PL PL16154186T patent/PL3045456T3/pl unknown
- 2013-05-03 RS RS20180076A patent/RS56784B1/sr unknown
- 2013-05-03 HU HUE13720407A patent/HUE029366T2/en unknown
- 2013-05-03 EP EP13720407.9A patent/EP2847190B1/de active Active
- 2013-05-03 CA CA2872906A patent/CA2872906C/en active Active
- 2013-05-03 ES ES13720407.9T patent/ES2581537T3/es active Active
- 2013-05-03 AU AU2013258223A patent/AU2013258223B2/en active Active
- 2013-05-03 CN CN201710219097.9A patent/CN106983751B/zh active Active
- 2013-05-03 NO NO16154186A patent/NO3045456T3/no unknown
- 2013-05-03 WO PCT/EP2013/059286 patent/WO2013167495A1/de not_active Ceased
- 2013-05-08 JO JOP/2013/0144A patent/JO3290B1/ar active
- 2013-05-08 TW TW106105676A patent/TWI635085B/zh active
- 2013-05-08 SA SA113340533A patent/SA113340533B1/ar unknown
- 2013-05-08 UY UY0001034797A patent/UY34797A/es active IP Right Grant
- 2013-05-08 AR ARP130101600A patent/AR090994A1/es active IP Right Grant
- 2013-05-08 TW TW102116308A patent/TWI579278B/zh active
2014
- 2014-11-02 IL IL235438A patent/IL235438A/en active IP Right Grant
- 2014-11-06 CU CU2014000129A patent/CU20140129A7/es unknown
- 2014-11-07 CL CL2014003031A patent/CL2014003031A1/es unknown
- 2014-11-07 CR CR20140513A patent/CR20140513A/es unknown
- 2014-11-07 PH PH12014502496A patent/PH12014502496B1/en unknown
- 2014-11-07 ZA ZA2014/08146A patent/ZA201408146B/en unknown
- 2014-11-07 TN TN2014000470A patent/TN2014000470A1/fr unknown
- 2014-11-07 DO DO2014000255A patent/DOP2014000255A/es unknown
- 2014-11-07 CO CO14246970A patent/CO7131375A2/es unknown
- 2014-11-07 EC ECIEPI201426138A patent/ECSP14026138A/es unknown
2016
- 2016-07-06 CY CY20161100636T patent/CY1118900T1/el unknown
- 2016-10-07 US US15/288,968 patent/US9949977B2/en active Active
- 2016-10-07 US US15/288,982 patent/US9949978B2/en active Active
2017
- 2017-05-02 JP JP2017091842A patent/JP6367421B2/ja active Active
- 2017-08-10 IL IL253950A patent/IL253950B/en active IP Right Grant
- 2017-11-22 AU AU2017265047A patent/AU2017265047B2/en active Active
2018
- 2018-01-23 HR HRP20180125TT patent/HRP20180125T1/hr unknown
- 2018-01-24 CY CY20181100095T patent/CY1119840T1/el unknown
- 2018-03-05 US US15/912,185 patent/US10300062B2/en active Active
2019
- 2019-04-02 US US16/373,487 patent/US20200061063A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TN2014000470A1 (en)	2016-03-30
TW201734007A (zh)	2017-10-01
JO3290B1 (ar)	2018-09-16
WO2013167495A1 (de)	2013-11-14
DOP2014000255A (es)	2015-02-27
EP2847190A1 (de)	2015-03-18
US10300062B2 (en)	2019-05-28
CN104395310B (zh)	2017-05-03
ZA201408146B (en)	2017-01-25
EA201492040A1 (ru)	2015-12-30
US20150148340A1 (en)	2015-05-28
US20180256576A1 (en)	2018-09-13
PL3045456T3 (pl)	2018-03-30
CR20140513A (es)	2014-12-02
CO7131375A2 (es)	2014-12-01
IL235438A (en)	2017-08-31
AU2017265047A1 (en)	2017-12-14
EP3045456A1 (de)	2016-07-20
HK1202873A1 (en)	2015-10-09
CU20140129A7 (es)	2015-02-26
SG10202003175QA (en)	2020-05-28
CN104395310A (zh)	2015-03-04
CL2014003031A1 (es)	2015-03-06
KR20150016548A (ko)	2015-02-12
KR102083281B1 (ko)	2020-05-29
MX357712B (es)	2018-07-20
ECSP14026138A (es)	2015-12-31
JP2015516000A (ja)	2015-06-04
HRP20180125T1 (hr)	2018-02-23
UY34797A (es)	2013-11-29
PL2847190T3 (pl)	2016-12-30
DK2847190T3 (en)	2016-07-25
AR090994A1 (es)	2014-12-30
LT3045456T (lt)	2018-02-12
US9949978B2 (en)	2018-04-24
SA113340533B1 (ar)	2015-10-12
TWI579278B (zh)	2017-04-21
ES2657315T3 (es)	2018-03-02
MX367599B (es)	2019-08-28
BR112014028086A2 (pt)	2020-12-01
EA201790032A1 (ru)	2017-05-31
CY1118900T1 (el)	2018-01-10
CY1119840T1 (el)	2018-06-27
SI3045456T1 (sl)	2018-03-30
RS56784B1 (sr)	2018-04-30
PT3045456T (pt)	2018-01-30
NO3045456T3 (sl)	2018-03-24
EP2847190B1 (de)	2016-04-06
JP2017160242A (ja)	2017-09-14
EA030383B9 (ru)	2018-12-28
PH12014502496A1 (en)	2015-01-12
PT2847190T (pt)	2016-07-14
US9949977B2 (en)	2018-04-24
AU2013258223A1 (en)	2014-11-27
CN106983751B (zh)	2020-01-07
PE20142301A1 (es)	2014-12-19
HRP20160796T1 (hr)	2016-08-12
DK3045456T3 (da)	2018-01-29
AU2013258223B2 (en)	2017-11-09
NZ701700A (en)	2016-09-30
HUE035462T2 (en)	2018-05-02
CN106983751A (zh)	2017-07-28
CA2872906A1 (en)	2013-11-14
TW201406744A (zh)	2014-02-16
US20170020876A1 (en)	2017-01-26
JP6367421B2 (ja)	2018-08-01
EA031222B1 (ru)	2018-12-28
ES2581537T3 (es)	2016-09-06
EP3045456B1 (de)	2017-10-25
MY181828A (en)	2021-01-08
IL253950A0 (en)	2017-10-31
BR112014028086B1 (pt)	2021-09-21
IL253950B (en)	2019-07-31
AU2017265047B2 (en)	2019-04-18
TWI635085B (zh)	2018-09-11
EA030383B1 (ru)	2018-07-31
PH12014502496B1 (en)	2015-01-12
RS54901B1 (sr)	2016-10-31
US20170020875A1 (en)	2017-01-26
US9481672B2 (en)	2016-11-01
HUE029366T2 (en)	2017-02-28
AP2014008096A0 (en)	2014-12-31
UA112897C2 (uk)	2016-11-10
JP6141414B2 (ja)	2017-06-07
MX2014013571A (es)	2014-12-08
CA2872906C (en)	2020-08-04
US20200061063A1 (en)	2020-02-27

Publication	Publication Date	Title
IL253950A0 (en)	2017-10-31	Cyclic-converted uracils and their use
IL237309A0 (en)	2015-04-30	Benzocyclooctyne compounds and uses thereof
IL239643A0 (en)	2015-08-31	Converted morphines and their use
EP2828258A4 (en)	2015-08-12	NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
IL237068A (en)	2017-12-31	1,3-dioxanomorphides and 1,3-dioxanocodides
EP3083606A4 (en)	2017-06-21	Pyrimidines and use thereof
GB201305277D0 (en)	2013-05-01	Novel combination and use
IL237926A0 (en)	2015-05-31	Combinations and their uses
ZA201501124B (en)	2016-04-28	Trans-clomiphene formulations and uses thereof
ZA201405392B (en)	2015-12-23	Substituted phenylimidazopyrazoles and use thereof
PT2855506T (pt)	2017-06-14	Péptido e utilização do mesmo
SG11201504482VA (en)	2015-07-30	Beta-hexosyl-transferases and uses thereof
IL237400A0 (en)	2015-04-30	Rhizobacteria and its uses
PL2895751T3 (pl)	2017-06-30	Śruba i jej zastosowanie
GB201305297D0 (en)	2013-05-01	Novel agents and uses thereof
GB201222342D0 (en)	2013-01-23	Compounds and uses thereof
GB201210667D0 (en)	2012-08-01	The sleep easy
GB201222541D0 (en)	2013-01-30	Kiddibidet and pottibidet
IL218974A0 (en)	2012-06-28	Conaction bitwen coutch and playels
GB201202021D0 (en)	2012-03-21	Co-sleeper and breastfeeder
GB201215414D0 (en)	2012-10-17	Composition and use
GB201213726D0 (en)	2012-09-12	Novel compounds and their use
GB201222307D0 (en)	2013-01-23	The hand
GB201201924D0 (en)	2012-03-21	The hand